Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. - Wikidata - wikimedia - TriplyDB

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

http://www.wikidata.org/entity/Q34621219

about

Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Novel Molecular Markers for Breast Cancer Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.Pathway-based analysis of breast cancer.Trastuzumab emtansine: mechanisms of action and drug resistance PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer.Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor.Identification of novel targets for breast cancer by exploring gene switches on a genome scale.Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review.Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.The history and future of targeting cyclin-dependent kinases in cancer therapy.Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Integrative genomic and functional profiling of the pancreatic cancer genome.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma Up-regulation of cyclin E in breast cancer via estrogen receptor pathway.Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Targeting cell cycle regulators in hematologic malignancies.Targeted therapies for breast cancer.Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Target points in trastuzumab resistance A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Two dimensions in targeting HER2.

P2860

Q22000752-DE6A4CAB-E805-45E3-A674-190F19679FA2 Q26752780-7DDB97C8-D5DD-4858-9F1F-579DB983D0C2 Q26753160-DB479105-BD29-4CA1-854C-1508EC350CA8 Q27316936-87233D3D-7AE6-4442-8690-D3C2606D6F45 Q27318931-9C80DC6A-C79B-4CF7-86C2-362D451EBDFB Q28544422-A84C5206-428A-4BA5-A4FE-595A05C1DD01 Q28829762-68988DEA-043A-47B5-A391-7E5B69276B1B Q33601653-925549D9-D4E9-43BB-BC25-46518C68A4B4 Q33737278-D98C6379-AA65-4060-99CA-BA5C536D8CEC Q33738675-82C0FC37-AD9B-4CD5-9CC6-6720E19E8443 Q33758011-687F74D7-5E66-4929-BEC7-7FAF7D2A0172 Q33759627-D3923798-AD5D-4D85-857B-B6A7E0282994 Q33782728-0ED8B0EF-D263-452A-97DE-F49145A59243 Q34062677-8606C2E5-E515-423E-AC6C-CC4E13EF54C4 Q34067222-242286D6-53DE-4D7A-A5C7-09E8570B1A55 Q34169075-11CB03B1-C45B-4DB4-BA7C-D85270DC52C3 Q34181700-C7D93752-C542-41A2-86C5-35A75CBB2F30 Q34308692-EBC84309-982C-4D49-AEB9-8DCCDEB4F98B Q34314172-304466BE-EE11-4680-9685-58A0EAAE8291 Q34452426-A63AEDD1-700B-4D0F-A5F7-5716F06C8A41 Q34460347-39788C46-3A14-498F-80DB-DAB4565C757C Q34483555-254B6337-C1E4-4A3E-8D3F-0AA5796E4F2A Q34489947-4369103F-4CF8-4C8E-B860-C6B5ABF7ED05 Q34615545-625F3153-755E-4082-9006-D94C3BE19C8F Q34664078-1A6733C3-0349-4BC7-A4E7-1B51AD32EF00 Q34990981-B55A569A-2267-4242-BE48-D1F1FF79D65F Q35079683-A4C5E7C5-CDFB-4583-93F0-6F42BFF7F412 Q35145369-873F2EA3-8EB3-4BD9-A7A4-240EB6111B0A Q35173653-EFA7F1D9-FECC-4D1E-ACB6-7B6B7FBAC0F6 Q35176400-60723801-5411-4661-8DA2-C1C24426A312 Q35237773-AD816953-9B05-4A5C-AD61-6FC98DF6361E Q35334436-BAF34E1C-C01E-44D7-82FE-7CFC9D449F86 Q35372584-3F570745-5819-45CE-B1D4-F9145C0D5D69 Q35521281-6D53F001-5F22-464D-92D1-5AC5204B6AC1 Q35624814-5263B7A1-6E30-446D-AF10-B60DACE93AD7 Q35684440-1BA4C38D-8DEC-4A2B-881C-C40A28D8E5F4 Q35821286-EA1B6D4D-AC5C-4B11-8409-5EBA972CE93C Q35878807-5DF3BD8E-8883-4693-A72D-4D8C067539CE Q35892045-0821EC96-2BA7-41AC-8274-B6F93CE574E5 Q35895143-B15F1BA6-3E07-4C3A-B91F-6EDE85609563

P2860

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

http://www.wikidata.org/entity/Q34621219

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@ast

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@en

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@nl

type

label

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@ast

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@en

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@nl

prefLabel

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@ast

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@en

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@nl

P1433

Q34621219-006C7F17-3FD8-4D73-8CC2-A0E118B4D5F1

P1476

Q34621219-85A21DF1-C4CA-4D89-9D22-C7E274AB721C

P2093

Q34621219-1F855440-8DEA-46E2-A70F-FC78BCDA68CC

Q34621219-3B61A1AE-8A1E-42E2-862B-308B5202DFD5

Q34621219-4038C422-62A1-4745-90B9-9A0DC398D572

Q34621219-6A84078C-7F6E-4189-BEE3-807B59F771C1

Q34621219-6DE8EE45-F5DC-4592-ABAE-A4CD944E664B

Q34621219-8F0353C2-3B8F-4E9D-8763-5D8BCB716751

Q34621219-A5B9A68B-B7AB-4062-8C90-BC4107BC1220

Q34621219-AA6DE9D6-7BA4-49F3-A23B-2645D136E03E

Q34621219-B42AFC3F-F3D2-4AC8-B368-544665C3CB2F

Q34621219-C3AB0558-62A1-4150-86BA-71BF84367DC0

P2860

Q34621219-1A75D074-D223-43C2-8E15-F04C341094B2

Q34621219-24E77162-9BA3-476C-9E1C-1A999AD98DC0

Q34621219-26695B2E-F89A-4C40-BA37-74F1179D2F22

Q34621219-28C6B072-5943-4D64-B822-3176DDC5E17F

Q34621219-2A59E0C6-4DFC-446F-B7DD-DB7E6B8AEA96

Q34621219-2E17DCE8-3C0F-407A-B7D6-20A5F52287CF

Q34621219-308BF650-31CF-4DC9-B985-E153E3EAF958

Q34621219-35FC01BB-DA5F-48F1-B096-77AD31780C7A

Q34621219-3686CFB0-A99E-4090-8AAB-61FB9F54014B

Q34621219-38EB9D08-8DAD-4BA4-B3C0-3DC70B10D6EF

P304

Q34621219-A8457664-1457-4646-A0D6-185A85B0910B

P31

Q34621219-08B8F1A4-37D1-4B83-9278-F4D6965C4964

P356

Q34621219-5CE3A328-20AA-415D-A439-66D72934111A

P407

Q34621219-EB873C38-D07F-4311-B773-C41248F3F9CB

P433

Q34621219-5FD93C23-B9A1-4122-95A3-CD7D3E772BC6

P478

Q34621219-C956A372-B47A-4BB7-924E-705EA7A3DEE7

P50

Q34621219-50FF82A6-97FB-494E-AFC4-ADE527589AF8

Q34621219-7D059955-40F6-4637-80B1-8EC40AD3B276

Q34621219-919F4855-85C5-477E-B95C-F536A1392B72

Q34621219-BC6E2FD2-74F8-435A-9620-C2E76C1D9F73

Q34621219-F36179D3-6A40-4EC1-9D3B-00439315B81F

P577

Q34621219-917AD101-ADB8-4F8A-9AFF-228FB0C6BD51

P5875

Q34621219-B36948CF-5262-4527-AF41-5C32057002DE

P698

Q34621219-46E7BE30-EC2E-47AE-A10F-E99724F600F1

P921

Q34621219-A54C0D03-51CA-4D7B-9C59-C73A9E95D5B5

Q34621219-D448899B-1E62-40CD-8FE3-E1037ED82BBC

P932

Q34621219-27F400B2-91EF-4239-9861-C43F4FA81201

P356

PNAS.1014835108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Cyclin E amplification/overexp ...... HER2+ breast cancer patients.

@en

P2093

Claudia Aura

http://www.w3.org/2001/XMLSchema#string

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

José Jiménez

http://www.w3.org/2001/XMLSchema#string

José Pérez

http://www.w3.org/2001/XMLSchema#string

Ludmila Prudkin

http://www.w3.org/2001/XMLSchema#string

Magui Gili

http://www.w3.org/2001/XMLSchema#string

Marta Guzmán

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy

Human cyclin E, a nuclear protein essential for the G1-to-S phase transition

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Cyclin E and survival in patients with breast cancer.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

P304

3761-3766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1014835108

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Pieter J Eichhorn

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836207

http://www.w3.org/2001/XMLSchema#string

P698

21321214

http://www.w3.org/2001/XMLSchema#string

P921

P932

3048107

http://www.w3.org/2001/XMLSchema#string